TY - JOUR
T1 - Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions
AU - Pisanic, Thomas R.
AU - Asaka, Shiho
AU - Lin, Shiou Fu
AU - Yen, Ting Tai
AU - Sun, Hanru
AU - Bahadirli-Talbott, Asli
AU - Wang, Tza Huei
AU - Burns, Kathleen H.
AU - Wang, Tian Li
AU - Shih, Ie Ming
N1 - Funding Information:
Supported by The Department of Defense Congressionally Directed Medical Research Programs grant W81XWH-11-2-0230; NIH/National Cancer Institute grants EDRN U01CA200469, R01CA215483, R01GM124531, P50CA228991, and P50GM107632; the Tina's Wish Foundation; the Ovarian Cancer Research Alliance; a TEAL award; the Mathers Foundation; the Richard W. TeLinde Endowment; and the Johns Hopkins Discovery Award.
Publisher Copyright:
© 2019 American Society for Investigative Pathology
PY - 2019/3
Y1 - 2019/3
N2 - There is growing evidence that most high-grade serous ovarian carcinomas likely arise from local dissemination of precursor lesions of the fallopian tube. Evolution of these lesions from early p53 signatures to latter-stage, serous tubal intraepithelial carcinomas (STICs) is characterized by cytologic atypia, accumulation of somatic mutations, and genomic instability, the etiologies of which remain unclear. Long interspersed element 1 (LINE-1) retrotransposon is expressed in many carcinomas, including high-grade serous ovarian carcinoma, where it contributes to genomic instability; however, the timing of LINE-1 activation during this evolution has yet to be elucidated. In this study, we assessed LINE-1 open reading frame 1 protein expression in 12 p53 signature lesions, 32 STICs, and 112 various types of ovarian cancers via immunohistochemical staining and examined LINE-1 promoter methylation in representative cases. We found that 78% and 57% of STICs, with and without concurrent ovarian carcinomas, respectively, exhibited intense LINE-1 immunoreactivity compared with adjacent, normal-appearing fallopian tube epithelium. Hypomethylation of the LINE-1 promoter was found in all STICs exhibiting overexpression. None of the 12 p53 signatures demonstrated significant LINE-1 expression. In ovarian cancer, 84 (75%) of 112 ovarian carcinomas overexpressed LINE-1. Our results indicate that LINE-1 retrotransposons often become deregulated during progression of ovarian cancer precursor lesions from the p53 signature to STIC stages and remain highly expressed in carcinoma.
AB - There is growing evidence that most high-grade serous ovarian carcinomas likely arise from local dissemination of precursor lesions of the fallopian tube. Evolution of these lesions from early p53 signatures to latter-stage, serous tubal intraepithelial carcinomas (STICs) is characterized by cytologic atypia, accumulation of somatic mutations, and genomic instability, the etiologies of which remain unclear. Long interspersed element 1 (LINE-1) retrotransposon is expressed in many carcinomas, including high-grade serous ovarian carcinoma, where it contributes to genomic instability; however, the timing of LINE-1 activation during this evolution has yet to be elucidated. In this study, we assessed LINE-1 open reading frame 1 protein expression in 12 p53 signature lesions, 32 STICs, and 112 various types of ovarian cancers via immunohistochemical staining and examined LINE-1 promoter methylation in representative cases. We found that 78% and 57% of STICs, with and without concurrent ovarian carcinomas, respectively, exhibited intense LINE-1 immunoreactivity compared with adjacent, normal-appearing fallopian tube epithelium. Hypomethylation of the LINE-1 promoter was found in all STICs exhibiting overexpression. None of the 12 p53 signatures demonstrated significant LINE-1 expression. In ovarian cancer, 84 (75%) of 112 ovarian carcinomas overexpressed LINE-1. Our results indicate that LINE-1 retrotransposons often become deregulated during progression of ovarian cancer precursor lesions from the p53 signature to STIC stages and remain highly expressed in carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85061841099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061841099&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2018.11.005
DO - 10.1016/j.ajpath.2018.11.005
M3 - Article
C2 - 30553834
AN - SCOPUS:85061841099
SN - 0002-9440
VL - 189
SP - 513
EP - 520
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 3
ER -